GlassScriptPhysician profile
Valji D Munjapara
NPI 1134212111
$16,608.42
in general payments reported to CMS, 2019-2025
67 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,444 · 2020: $1,827 · 2021: $1,909 · 2022: $2,250 · 2023: $2,668 · 2024: $2,506 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,099 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,098.58 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,897.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,869.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,561.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,232.12 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $889.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $706.81 | 2019-2024 | Spravato, Xarelto |
| Pfizer INC. | $659.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.26 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $536.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $520.39 | 2019-2025 | |
| Olympus America INC. | $420.44 | 2025 | Itind System |
| Amarin Pharma, INC. | $409.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $342.92 | 2019-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $326.33 | 2020-2025 | Rexulti, Jynarque, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.12 | 2022-2025 | Xifaxan, Trulance |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valji Munjapara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.